Post Operative Adjuvant Chemotherapy Followed by Adjuvant Tamoxifen vs Nil for Patients With Operable Breast Cancer

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00538330

Enrollment

2000

Registered

2007-10-02

Start date

2007-09-30

Completion date

2020-09-30

Last updated

2011-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

Post operative adjuvant chemotherapy followed by adjuvant Tamoxifen vs nil for patients with operable breast cancer

Interventions

DRUGTamoxifen

Tamoxifen

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients with operable breast cancer

Design outcomes

Primary

Measure	Time frame
safety	10 years

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026